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Abstract.  Interaction of the vascular cell adhesion 
molecule (VCAM-1) with its counter-receptor very late 
antigen-4  (VLA-4) (integrin  ot4fl0 is important  for a 
number of developmental pathways and inflammatory 
functions.  We are investigating the molecular mecha- 
nism of this binding,  in the interest of developing new 
anti-inflammatory drugs that block it.  In a previous 
report,  we showed that the predominant form of 
VCAM-1  on stimulated endothelial cells, seven-domain 
VCAM (VCAM-7D), is a  functionally bivalent mole- 
cule.  One binding  site requires the first and the other 
requires the homologous fourth immunoglobulin-like 
domain.  Rotary shadowing and electron microscopy of 
recombinant soluble VCAM-7D molecules suggests 
that the seven Ig-like domains are extended in a  slightly 
bent linear array,  rather than compactly folded to- 
gether.  We have systematically mutagenized the first 
domain of VCAM-6D (a monovalent, alternately 
spliced version missing domain 4) by replacing 3-4 
amino acids of the VCAM sequence with correspond- 
ing portions of the related ICAM-1  molecule.  Specific 
amino acids important  for binding VLA-4 include 
aspartate 40 (D40), which corresponds to the acidic 
ICAM-1  residue glutamate 34 (E34) previously re- 
ported to be essential for binding of ICAM-1  to its 
integrin counter-receptor LFA-1. A  small region of 
VCAM including D40,  QIDS, can be replaced by the 
similar ICAM-1  sequence, GIET,  without affecting 
function or epitopes, indicating that this region is part 
of a general integrin-binding  structure rather than a 
determinant of binding specificity for a particular inte- 
grin.  The VCAM-1  sequence G65NEH also appears to 
be involved in binding VLA-4. 
T 
~E interaction of cells with one another via their mem- 
brane-bound adhesion  molecules is a  dynamic pro- 
cess with multiple  physiologic  and pathologic  conse- 
quences.  Molecular  regulation  of cellular  adhesion  and 
de-adhesion is responsible for modeling of the tissues and or- 
gans during development,  and many of the same molecules 
continue to be important in both repair and normal function 
in the adult. Since its discovery a few years ago, the vascular 
cell  adhesion  molecule-1  (VCAM-1)l/very  late  antigen-4 
(VLA-4)  adhesion  pathway has been shown to be involved 
in embryonic development of skeletal muscle (Rosen et al., 
1992), and in hematopoiesis (Miyake et al., 1991), in addi- 
tion to its originally  described function as an inducible vas- 
cular adhesion  pathway involved in migration  of mononu- 
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1. Abbreviations  used in this paper:  VCAM-1, vascular cell adhesion mole- 
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clear leukocytes to  sites  of inflammation  (Osborn et al., 
1989;  Elices et al.,  1990).  It has  been implicated  in the 
pathology of disorders affecting a wide range of processes, 
including metastasis of tumors (Rice and Bevilacqua,  1989), 
atherosclerosis  (Cybulsky and Gimbrone,  1991), and auto- 
immune encephalitis  (Yednock et al.,  1992). 
VCAM-1 (also called INCAM-110) (Rice and Bevilacqua, 
1989) is an Ig superfamily  protein which is synthesized by 
endothelial cells in response to IL-1, TNF, LPS, or IL-4, and 
is found constitutively on a few other cell types, such as fol- 
licular  dendritic  cells in  lymph  nodes  (Freedman  et al., 
1990) and bone marrow stromal cells (Miyake et al., 1991). 
The  first  counter-receptor  identified  for VCAM  1 was  a 
member of  the heterodimeric integrin family known as VLA-4 
or a4~1, found on most mononuclear leukocytes, but not on 
neutrophils.  VLA-4 can also bind to an alternately  spliced 
site in fibronectin  called CS-1 (Wayner et al.,  1989; Guan 
and Hynes,  1990). The ct4 integrin chain in association with 
a different beta chain,  a4f17 or ol4flp, appears  to be capable 
of binding  to both VCAM-1 and fibronectin  (Ruegg et ai., 
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covered Ig molecule known as mucosal addressin cell adhe- 
sion molecule-1  (MAdCAM-1) (Briskin et al.,  1993; Berlin 
et al.,  1993). 
Within the Ig superfamily, VCAM-1 belongs to a growing 
subfamily of cell surface molecules including ICAMA, -2, 
and  -3,  and  MAdCAM-1,  that  bind  leukocyte  int~grin 
ligands.  Members of this  family are distinguished by the 
presence of four cysteine residues instead of the usual two, 
in domains important for counter-receptor binding. Here we 
show by  rotary  shadowing and electron microscopy that 
purified recombinant VCAM-1, like ICAM-1 and the immu- 
noglobulins, assumes an extended conformation rather than 
a more compactly folded tertiary structure. 
VCAM-1 exists in two alternately spliced forms on en- 
dothelial cells, a major form comprised of seven Ig-like do- 
mains (VCAM-7D),  and a  minor form lacking domain 4 
(VCAM-6D)  (Fig. 1) (Cybulsky et al., 1991; Hession et al., 
1991). Previously we showed that VCAM-7D has two homol- 
ogous  binding  sites  for  VLA-4,  one  requiring  the  first 
(NH2-terminal)  Ig-like domain (D1) and the other requiring 
the fourth (I)4) (Vonderheide and Springer, 1992; Osborn et 
al.,  1992).  It is probable that the mechanism of binding to 
VLA-4 is the same for these two domains, as they are very 
similar in sequence, having only 11 nonconservative amino 
acid differences within the 90-amino acid domain, and can 
substitute  for each other  structurally and  functionally in 
recombinant constructs. To map more finely areas of  the pro- 
tein structure required for binding to VLA-4, we have syste- 
matically mutagenized domain 1 and analyzed the mutant 
constructs for maintenance of functional mAb epitopes and 
cell binding activity. 
Materials and Methods 
Rotary Shadowing  and Electron Microscopy 
Purified rsVCAM-7D or equimolar mixtures of rs~V.AM  and antibody were 
incubated at 4oC for I h at 0.5-1 mg/ml in PBS. 1-2-/d samples were rapidly 
mixed  with ice-cold  40-45 % glycerol,  sprayed  onto mica and platinum- 
rotary shadowed  at a glancing angle of 6-8 degrees.  Micrographs were 
taken at a magnification of 48,000 and selected images from scanned prints 
were measured using the program Image 1.45 (NIH). A JEOL  100CXII 
operating at 80 KV was used.  After each electron microscopy  session, the 
microscope was calibrated with negatively stained images of T4 phage tails 
(4.1 nm repeat period). 
Antibodies and Cells 
Previously described monoclonal antibodies used were anti-o~4, HPI/2 (PU- 
lido et al.,  1991); and anti-VCAM-1, 4139 (Carlos et al.,  1990).  EH8 is an 
IgGl mAb made from mice immunized with recombinant soluble VCAM- 
7D (Lobb et al., 1991), and will be described in detail elsewhere (Benjamin, 
C.,  and I.  Dougas,  unpublished data), mAb BBA-5 was purchased from 
R & D Systems, Inc.  (Minneapolis, MN). mAb epitopes were mapped by 
FACS analysis of COS'/cells transfected with ~..AM/ICAM chimeric con- 
structs previously  described (Osborn et al.,  1992),  and by analysis of hu- 
man/murine  chimeric constructs (Hessiun,  C., and D. Worley, Bingen, Inc., 
unpublished  results). Polyclonal rabbit  anti-VCAM-1 serum was made by in- 
ocolafing  rabbits with recombinant soluble VCAM-7D. COS7 and Ramos 
cells were cultured as previously  described (Osborn et al.,  1989). 
Protein and Nucleic Acid Sequence Analysis 
Sequence analysis was carried out using the GCG Package (Genetic Com- 
puting Group, Madison, WI). 
Figure 1. Schematic diagram of two alternately spliced forms of hu- 
man VCAM-1, VCAM-7D, and VCAM-6D. Domains implicated in 
ligand binding are shaded. 
Mutant Constructions 
Mutants were constructed using a modification of the gapped-heteroduplex 
oligonucleotide-directed  mutagenesis technique.  Aliquots of the  parent 
plasmid VCAM41/CDM8 (VCAM-6D) (Osborn et al., 1989) were digested 
by restriction endonuclease MluI to generate a full-length linear molecule, 
or by HindlII and BspHI to generate a gapped linear molecule, and the large 
fragments were agarose gel purified.  Approximately  four pmoles of phos- 
phorylated mutagenic  oligonucleotide  and 50 ng each of full-lengdi  and 
gapped template fragment in 10 #1 of 0.1 M NaCI,  6.5 raM TrisCl pH 7.6, 
and 8 mM MgCI2 was placed in a beaker of boiling water, which was then 
allowed to cool to RT. All four deoxyribonucleotides  to 0.5 mM each, ATP 
to 1 raM, 1 #1 of Klenow fragment and 0.5 ~d of T4 DNA ligase were added 
to a final volume of 20 #1, and incubated at 15°C overnight. DNA was etha- 
nol precipitated and electroporated into bacterial host strain MC1061/p3 
using a  Bio  Rad  Gene Pulser  (Bio  Rad  Laboratories,  Richmond,  CA) 
Clones were screened by colony lift followed by hybridization with the ra- 
diolabeled mutagenic oligonucleotide  by standard methods.  At least one 
isolate of each clone was sequenced across the original gap using a Se- 
quenase kit from United States Biochemical Corp.  (Cleveland,  OH). 
Ceil-Ceil Adhesion Assays and Flow Cytometry 
Mutant constructs were transfected into COS7 cells by electroporation and 
analyzed by FACS and plate binding assays after 48-72 h as previously  de- 
scribed (Osborn et al., 1992). Binding of Ramos cells and mAbs to transfec- 
tants was normalized for relative expression as assessed  by staining with 
mAb EH8, which recognizes  an epitope insensitive to folding of domains 
I  and  2,  then calculated  as  a  percentage of  wild-type (VC.AM-6D) binding. 
Ramos cell binding to all mutants was confirmed to be VLA-4-mediated  by 
blocking with anti-or4 mAb HP1/2. 
Results and Discussion 
Visualization of VCAM-1 by Electron Microscopy 
Because mAb 4B9, which binds to domain 1, is capable of 
blocking both domain 1 and domain 4-dependent binding to 
VLA-4 (Vonderheide and  Springer,  1992;  Osborn  et al., 
1992),  we  had  considered  that  the  VCAM-TD  molecule 
might be folded so that the domain 1 and domain 4-depen- 
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Some molecules are straight and others show one or two bends along the long axis of the molecule. Bar, 40 nm. 
dent binding sites are in close proximity. To determine the 
general shape of the VCAM-7D molecule, rotary shadowing 
electron microscopy was performed. Fig. 2 shows an exam- 
ple of  a general field of  recombinant soluble VCAM-7D.  Two 
classes of images were observed, corresponding to straight 
and bent rods (see selected views in Fig. 3). The straight rod- 
shaped structures, representing ,o25 % of the molecules, are 
28.1  +  4.4 nm in length and 5.7  um in width  (Fig.  3  k). 
Sometimes these images show an enlargement or small bend 
at one end of the molecule (Fig. 3 k and l, right molecule). 
The bent rods, the remainder of the population, display ei- 
ther one or two bends along the long axis of the molecule. 
In the images with one bend, the bend has an angle of 115 ° 
+  32",  and is located about two thirds down the length of 
VCAM-TD,  dividing it into a long and a short arm (Fig. 3, 
1-o).  The long arm is 18.0 +  2.6 um long, and the short arm 
is 12.4 +  2.5 um long. The total length of the one-bend mol- 
ecules is greater than that of the straight molecules, at 30.4 
+  2.6 urn. In the molecules with two bends, the additional 
bend is located at variable positions in the short arm (Fig. 
3 l, left molecule and Fig. 3 m); the molecule is Z-shaped, 
and the overall length is 31.4 -t- 3.4 nm. It is probable that 
at least some of  the molecules that appear straight in fact rep- 
resent foreshortened views of molecules with one or two 
bends. Therefore, we take the measurements of  the bent mol- 
ecules to be a better reflection of  the overall length of  VCAM- 
7D. To obtain the actual length of  the molecule, the measure- 
ments along the long axis were corrected by subtraction of 
2.5 nm at each end of the molecule to take into account the 
increase in size due to the platinum particles deposited dur- 
ing shadowing.  The corrected length of the molecule is there- 
fore 25.9 urn. Since the width of VCAM-7D is comparable 
with the size of two Pt grains, making the same correction 
for this dimension would give a necessarily inaccurate num- 
ber. We therefore prefer not to give corrected figures for the 
width of VCAM-TD. Taking the extended length of  the mole- 
cule to be 25.9 nm,  each Ig domain contributes ,o3.7 nm 
to the overall length of the molecule. This is in good agree- 
ment with previous observations on the length of Ig domains 
(Staunton et al.,  1990; Wtlliams and Barclay,  1988). 
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immuno-compleges  formed 
between  VCAM-7D  and  the 
monoclonai  antibodies  4B9 
(specific for an epitope in do- 
main 1) and EDI1, GE4, and 
GEl2 (specific for epitopes in 
domain 4).  a-d  show  views 
and  e  shows  a  schematic 
representation  with  a  single 
point  of  contact  between 
VCAM-7D  and  4B9. f-g,  h, 
and  i  correspond  to  typical 
views  of immuno-complexes 
formed  between  VCAM-7D 
and  antibodies  GEl2,  EDll 
and GE4, respectively, j  is a 
representation  of the binding 
of any of these antibodies  to a 
site on the convex side of the 
bend of VCAM-TD. (k-o) are 
images  of straight  and  bent 
single  VCAM-TD molecules. 
Bar, 40urn. 
To examine the arrangement of the Ig domains in VCAM- 
7D, we visualized complexes of VCAM-TD with the mAbs 
4B9, which maps to domain 1, and EDll,  GH12 and GE4, 
which map to domain 4.  mAb 4B9 always binds to an end 
of the molecule (Fig. 3, a-e),  often cross-linking two mole- 
cules (Fig.  3, a,  b, and d).  The angle of the bend in these 
complexed molecules is not statistically  different from the 
free molecules. In contrast, each of  the antibodies to domain 
4 bind on the convex face of the bend (Fig. 3,f-j),  again fre- 
quently  cross-linking  two  VCAM-TD  molecules  (Fig.  3, 
f-h).  The angle of the bend is similar to the angle in the bend 
of free VCAM-TD.  Thus  it is clear that the Ig domains of 
INTEGRIN 
LIOAND: 
1  hlCAMI  d3  QLVSPRVLEVDTCGTVVCSLD-GLFPVSEAQVHL---ALGDORL-NPTVTYGNDSFSAKAS-VSVTAEDEGTQRL  TCAVILGNQSQETLCTVTIYSF  hMAC-I 
2  hICAM2  dl  EVHVR•KKLAVE•KGSLEVNCSTT-CNQ•EV---GGLETSL-NKILLDEQAQWKHY•--VSNISHDTVLQCHFTCSGKQESMNSN-SVYQP-PRQ  hLFA-I 
3  hICAM3  dl  QEFLLRVEPQNPVLSAGGSLFVNCSTD-CPSSEK---IALETSL-SKELVASGMGWAAFN-  LSNVTGNSRILCSVYCNGSQITGSSNITVYGL-PER  hLFA-I 
4  ICAMI  dl  beta:  aaaaaa  bbbbbbbb-b  cc  cccc  dddddd  eeeee  eeee  ffffffff  ggggggggg 
5  CON(VI&Ildl)  p  psxP  b  hh  GsSf  fTCST  -CapP  h  laxPL  K  Gppp  fp  fS  nEcSph  CpspC  appp  Lph  ox  Pcc 
6  hICAMI  dl  QTSVSP-SKVILPRGGSVLVTCSTS-CDQPKL--  LGI~TPLPKKELLLPGNNRKVYE--LSNVQEDSQPMCYSNCPDG~STAKTFLTVYWT-PER  hLFA-] 
7  hVCAM  dl  FKIETTPESRYLAQIGDSVS~TCSTTGC~SPFFSWRTQI~SPLNGKVTNE-GTTSTLTMN~VSFGN~HSYL-CTATC-ESRKLEKGIQVEIYSFPKD  hVLA-4 
8  d4  FTvEIS~GPRIAAQIGDSVMLTCSVMGCES~SFSWRTQI~S~LSGKVRSE-GTNSTLTLSPVSFENEHSYL-CTVTC-GHKKLEKGIQVELYSF~RD  hVLA-4 
9  mVCAM  dl  FKIEIS~EYKTIAQIGDSMALTCSTTGCES~LFSWRTQI~S~LNAKVRTE-GSKSVLTME~VSFENEHSYL-CTATC-GSGKLERSIHVDIYSFPKD  hVLA-4 
I0  rVCAM  dl  FKIEIS~EYKTLAQIGDSMLLTCSTTGCESPSFSWRTQI~SPLNGKVKTE-~AKSVLTMD~VSFENEHSYL-CTATC-NSGKLERGIQVDIYSF~KD  hVLA-4 
ii  CON(V)  F  fE  xPp  c  hAQIGDSf  LTCSs  OCESP  FSWRTQIDSPLpsKVppE  GspS  LTfpPVSFpNEHSYL  CTsTC  sppKLEbpIpVafYSFPbD  hVLA-4 
12  VCAM  dl  beta:  aaaaa  bbbbb  cccccccc  dddd  eeeeeeee  (f  fffff  f)  gggggg 
13  CF  2deg  HHHHHHTTttBBBBB...BBBBBttTT.tt.BBBBBBBB..tttt...tt  tbbbbbbtttt.tt.tt..h  hhhhh  hhhhhhh.  BBBBBB...hh 
14  OOR  2deg  HH  .....  TTTBBBBBTTT.TTTTTTTTTT.TTTTT.TTT  ....... BBBB  ....  BBBBB ....  TTTTTTT  THHHH  HHHHHhh.  SBBSBB ..... 
a  -  acidic  -  D,E  f  -  aliphatic  -  L,I,V  z  -  aromatic  -  Y,F,W 
b  -  basic  -  H,K,R  h  -  hydrophobic  -  L,I,V,M,Y,F  p  polar  K,R,H,D,E,Q,N,T,$ 
c  -  charged  -  D,E,H,K,R  n  -  amine  -  N,Q  s  small  -  A,G,S,T,V,N,D 
x  -  hydroxyl  -  S,T 
Figure 4.  Comparison of Ig-like domains involved in integrin binding.  From top to bottom: (/) human ICAM-1 domain 3 (Staunton et 
al.,  1990;  Diamond et al.,  1991); (2) human ICAM-2 domain 1 (Staunton et al.,  1989);  (3) human ICAM-3 domain 1 (Vazeux et ai., 
1992; Fawcett et al.,  1992); (4) ICAM-1 domain 1 fl strand predictions  (Statmton  et al.,  1988); (5) conserved residues  between human 
ICAM-1 domain 1 and all VCAM-1 domains below; (6) human ICAM-1 domain 1 (Staunton et al.,  1988); (7) human VCAM-1 domain 
1 (Osbom et al.,  1989);  (8) human VCAM-1 domain 4 (Polte et al.,  1990);  (9) mouse VCAM-1 domain 1 (Hession et al.,  1992);  (10) 
rat VCAM-1 domain 1 (Hession et al.,  1992); (11) conserved residues  between VCAM-1 domains that bind human VLA-4; (12) predicted 
hVCAM-1 domain 1 secondary structure based on computer-generated predictions,  below; (13) Chou-Fasman (CF) secondary structure 
prediction, H and h = helical,  Tand t = beta turn, B and b =/3 strand (uppercase =  strong, lowercase =  weak); (14) Gamier-Osgnthorpe- 
Robson (GOR) secondary structure prediction, H =  helical,  T =  turn, B =  beta. The sequences were aligned by inspection  (the ICAM-1 
domain 3 sequence is less homologous than the others, and was only aligned in regions important for binding).  Residues underlined have 
been shown to be required  for binding to integrin  ligends. 
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EH8  1G 11  14C3  BBA6  4B9  61)9  1  E5  Ramos 
Parent  VCAM-6D  100  100  100  100  100  100  100  100 
F 1KIETT/-QTSVS  M 1  100  74  93  1  26  0  20  9 
R10YL/KVI  M2  100  98  109  126  227  88  95  304 
A 13QI/LPR  M3  100  86  82  15  2  0  0  6 
D17SVS/GSVL  M4  0 
T26CK2E/S-CD  M6  0 
S30PFF/QPKL  M7  100  120  100  147  0  116  74  176 
S34WRT/---L  M8  100  72  109  12  0  0  7  10 
Q38IDS/GIET  M9  100  110  120  142  69  131  106  82 
Q38IDS/AAAA  M23  100  93  97  133  66  125  79  0* 
Q38/A  M24  100  97  96  124  114  121  81  110 
IM0/A  M25  100  105  109  139  44  127  92  5* 
S41/A  M26  100  103  91  136  114  131  89  155 
N44/S  M27  100  115  96  133  75  113  83  143 
T48NE-/LLLP  M 11  100  89  109  11  2  0  15  35 
T52TST/NNRK  M 12  100  91  84  0  2  0  0  11 
L56TMN/VYE-  M 13  100  91  84  12  0  3  3  0 
V61SF/LSN  M 14  100  74  107  25  2  3  0 
G64NEH/VQED  M 15  100  112  125  73  58  43  75  8 
G64/A  M28  100  78  86  0  0  0  0  0 
N65/A  M29  100  109  107  90  63  32  91  3211 
H67/A  M30  100  100  105  117  128  69  101  154 
T72AT/YSN  M17  100  70  66  0  0  0  0  0 
K79LE/STA  M 19  100  60  67  33  43  26  38  58 
G83IQV/TFLT  M20  100  74  88  20  12  0  20  0 
E87IYS/VYWT  M21  0 
Percent wild-type binding aRer normalization for expression as determined by binding to mAb EH8 (to unaffected domain 5) was averaged for 2-7 experiments 
in each case. 
*n  =2, SD=O. 
*n  =  4, SD  =  5.8. 
~n  =7,  SD  =7.3. 
IIn  =4,8D  =  7.0. 
VCAM-7D are linearly arranged, like other molecules com- 
posed of Ig domains such as ICAM-1 (Kirchhausen et al., 
1993) and CD4 (Kirchhausen, T., and S. Harrison, unpub- 
lished data). Therefore the ability of mAb 4B9 to block do- 
main 4-dependent  binding  of VCAM-7D to VLA-4 must 
have an alternative explanation. 
Design of  Mutant Constructs 
Previously we showed that there are two independent bind- 
ing sites for VLA-4 in VCAM-7D, one requiring domain  1 
and the other requiring  domain 4.  The alternately  spliced 
VCAM-6D, which is missing domain 4, has only one func- 
tional VLA-4 binding site,  requiring domain 1. To simplify 
analysis of mutants, VCAM-6D was used as the parent con- 
struct  from which to derive  a  series  of mutants,  each  of 
which has one or more amino acid changes in domain 1. The 
VCAM-1 sequence was analyzed preliminarily using the pro- 
gram PeptideStructure,  which predicts secondary structure 
according  to  the  algorithms  of Chou-Fasman  (CF)  and 
Garnier-Osguthorpe-Robson (GOR). Prediction of the posi- 
tion of fl strands and loops in VCAM-1 domain 1 was done 
by making modest use of these predictions, and more exten- 
sive use of homology with known Ig domain structures. We 
chose to mutagenize both predicted loops and strands, rather 
than attempt to target the loops, where contact residues are 
generally  expected  to be  found.  We  and  others  find  that 
predictions of secondary structure,  while useful in the ab- 
sence of physical data, are often later shown to be somewhat 
inaccurate compared with physical data generated by NMR 
or x-ray crystallography (Barclay,  1992). Furthermore, evi- 
dence that binding sites are likely to be found in loops rather 
than strands is based largely on analogy with hypervariable 
antibody complementarity determining regions. It is possi- 
ble that more distantly related Ig superfamily members like 
VCAM-1  might  show  a  different  organization  of binding 
sites. 
Construction, Expression,  and Assay of 
Mutant Constructs 
Amino acids to be mutated were exchanged for the analo- 
gous amino acids found in ICAM-1 domain 1 (Fig. 4). This 
was  done  with  the  expectation  that  analogous  sequences 
from a related protein might stabilize the resulting mutant's 
structure; since we changed several contiguous amino acids 
in each mutant,  the common approach of substituting with 
alanine or serine residues would have resulted in extremely 
unnatural proteins. 
Mutant constructs were made using gapped-heteroduplex 
oligonucleotide-directed mutagenesis, as described in Mate- 
rials and Methods. After transfection into COS cells, expres- 
sion was assessed  by FACS analysis  using  antibody EH8, 
which binds between the NH2-terminal portion of domain 5 
and the COOH terminus of the protein, in an area unaffected 
by the mutagenesis.  Maintenance of proper folding of each 
mutant  was assessed  by analysis of binding to a  panel  of 
mAbs (see below). Ability of mutants to bind to VLA-4 was 
Osborn et al. Shape and Functional Amino Acids of VCAM-1  605 Conserved:  p  psxP  Sbhfh  GpSV  fTCSTx  CapP  h  pIaxPL  pK  Gppppfp  fS  nEcSph  CpspC  aspp  Ksh  ox  Pcc  mAbs: 
ICAMI  dl  beta:  aaaaaa  bbbbbbbb-b  cc---cccc  dddddd  eeeee--eeee  ffffffff  ggggggggg  Ehlgl4Bb4b6dle 
ICAMI  dl  QTSVSP-SKVILPRGGSvLVTcSTS-CDQ~KL---LGIETpLpKKELLL~GNNRKVYE--LSNVQEDSQPMCYSNC~DGQSTAKTFLTVYWT-~ER  -  +  -  +  +  -  +  Block 
VCAMI  dl  FKIETT~ESRYLAQIGDS~LTCSTTGCESpFFSWRTQIDSpLNGKVTNE-GTTSTLTMN~V~FGNEHSYL-CTATC-ESRKLEKGIQVEIYSF~KD  5  2  2  2  i  i  1  Domain 
VCAMI  dl  beta:  aaaaa  bbbbb  cccccccc  dddd  eeeeeeee  (f-fffff-f)  gggggg  Bind 
Mutant:  Ramos: 
M  I  -~PE~RYLAQIGDSVSLTCSTT~CES~FFSWRTQIDSPLNGKVTNE-GTT~TLTMNPVSFGNEHSYL-CTATC-ESRKLEKGIQVEIYSFPKD  +  +  +  -  ~  - 
M  2  FKIETTP-Sz~M~AQIGD~VSLTCSTTGCES~FFSWRTQIDS~LNGKVTNE-GTTSTLTMN~VSFGNEHSYL-CTATC-ESRKLEKGIQVEIYSF~KD  +  +  ÷  +  ÷  ÷  +  + 
M  3  FKIETT~ESRYLLpRGDS~SLTCSTTGCESpFFSWRTQIDS~LNGKVTNE-GTTSTLTMNP~SFGNEHSYL-CTATC~ESRKLEKGIQVEIYSF~KD  ÷  +  +  ~  .... 
M  4  FKIETT~ESRY~AQI~SV~LTCSTTGCES~FFSWRTQIDSPLNGKVTNE-GTTSTLTMNPVSFGNEHSYL-CTATC-ESRKLEKGIQVEIYSF~KD  - 
M  6  FKIETTPESRYLAQIGD$VSLTCSTB-C~SpFFSwRTQID$pLNGKVTNE-GTTSTLTMNPVSFGNEHSYL-cTATC-ESRKLEKGIQVEIYSFPKD  - 
M  7  FKIETT~ESRYLAQIGDSVSLTCSTTGCE~KLSWRTQIDS~LNGKVTNE-GTT~TLTMN~VSFGNEHSYL-CTATC-ESRKLEKGIQVE~YSF~KD  +  +  +  +  -  +  +  + 
M  8  FKIETTPESRYLAQIGDSVSLTCSTTGCESpFFr-z-%TQIDSPLNGKVTNE-GTTSTLTMN•VSFGNEHSYL-CTATC-E•RKLEKGIQVEIYSF•KD  +  +  +  ~  .... 
M  9  FKIETTPESRYLAQIGDSVSLTCSTTGCESPFF~WRT~K~LNGKVTNE-GTTSTLTMNpV~FGNEHSYL-CTATC-ESRKLEKGIQVEIYSF~KD  +  +  +  +  +  +  +  + 
M23  FKIETT•ESRYLAQIGDSVSLTCSTTGCESPFFSWRTAAAA•LNGKVTNE-GTTSTLTMNpV•FGNEHSYL-CTATC-ESRKLEKGIQVEIYSF•KD  +  +  +  -  +  +  ÷ 
M24  FKIETTpESRYLAQIGDSVSLTCSTTGCES~FF~RT~IDSPLNGKVTNE-GTTSTLTMN~SFGNEHSYL-~TATC-ESRKLEKGIQVEIYSF~KD  +  +  +  ÷  +  +  +  + 
M25  FKIETTPEsRYLAQIGDSVSLTCSTTGCES~FFSWRTQIASpLNGK~TNE-GTT$TLTMNPVSFGNEHSYL-CTAT~-ESRKLEKGIQVEIYSF~KD  +  +  ÷  +  ±  +  + 
M26  FKIETTpE~RYLAQIGDSVSLT~TTGCE~FFSWRTQIDAPLNGKVTNE-GTTSTLTMN~V~FGNEHSYL-CTATC-E~RKLEKGIQVEIYSFPKD  +  +  +  +  +  +  ÷  ÷ 
M27  FKIETT~ESRYLAQIGDSVSLTCSTTGCES~FFSWRTQIDSpL~GKVTNE-GTTSTLTMN~VSFGNEHSYL-CTATC-ESRKLEKGIQVE~YSF~KD  +  +  +  +  +  +  +  + 
MII  FKIETT•ESRYLAQIGDS•SLTC•TTGCES•FFSWRTQIDS•LNGKVLLL•GTTSTLTMN•VSFGNEHSYL-CTATC-ESRKLEKGIQVEIYSF•KD  +  +  +  ±  -  -  +  + 
MI2  FKIETT~ESRYLAQIGDSVSLTCSTTGCESPFFSWRTQIDS~LNGKVTNE-G~p-KLTMN~VSFGNEH~YL-CTATC-E~RKLEKGIQVEIYSF~KD  +  +  +  .... 
MI3  FKIETT~ESRYLAQIGDSVSLTCSTTGCES~FFSWRTQID~LNGKVTNE-GTTST~-~SFGNEHSYL-CTATC-ESRKLEK~IQVEIY~F~KD  +  +  +  ±  .... 
MI4  FKIETT~ESRYLAQIGDSVSLTCSTTGCES~FF3WRTQID~LNGKVTNE-GTT~TLTMN-LS~GNEHSYL-CTATC-E$RKLEKGIQVEIYSFpKD  +  +  +  ±  -  - 
MI5  FKIETTPE~RYLAQIGDSV~LTCSTTGCE~FFSWRTQID~LNGKVTNE-GTTSTLTMNPVSF~F~SYL-CTATC-ESRKLEK~IQVEIYSF~KD  +  +  +  +  +  ~  ÷ 
M28  FKIETTPESRYLAQIGDSVSLTCSTTGCES~FFSWRTQIDSPLNGKVTNE-GTTSTLTMN~VSFl&NEHSYL-CTATC-ESRKLEKGIQVEIY~FpKD  +  +  +  ..... 
M29  FKIETT~ESRYLAQIGDS~SLTCSTTGCES~FF~WRTQIDS~LNGKVTNE-GTT~TLTMN~VSFG~EHSYL-CTATC-ESRKLEKGIQVEIYSF~KD  ÷  +  +  +  +  &  + 
M30  FKIETTPESRYLAQIGDSvSLTCSTTGCES~FFSWRTQIDSPLNGKVTNE-GTTSTLTMNpVSFGNF~$YL-CTATC-ESRKLEKGIQVEIYSFPKD  +  +  +  +  +  +  +  + 
MI7  FKIETTPESRYLAQIGDSVSLTC~TTGCE~FFSWRTQIDSPLNGKVTNE-GTTSTLTMN~SF~NEH~YL-~-ESRKLEKGIQVEIYSFPKD  +  +  +  ..... 
MI9  FKIETTPESRY~AQIGDSVSLTCSTTGCE~FFS~RTQIDsPLNGKVTNE-GTTSTLTMNPVSFGNEHSYL-CTATC-ESR~-TAKGIQVEIYSFPKD  +  ÷  +  +  +  +  ÷  + 
M20  FKIETTPESRYLAQIGDSV~LTCSTTGCESpFFSwRTQIDS~LNGKVTNE-GTTSTLTMNPVSFGNEHSYL-CTATC-ESRKLEK~FLYEIYSF~KD  +  +  +  ~  Z  - 
M21  FKIETTpE~RYLAQIGDSVSLT~STTGCES~FF~WRTQID~PLNGKVTNE-GTT~TLTMN~V~FGNEH~YL-CTATC-E~RKLEKGIQV-~F~KD  ± 
Figure 5. Binding of human VCAM-1 domain-1 mutant constructs expressed in cos cells to VLA-4 and mAbs. Alignment of VCAM-1 to 
ICAM-1 and prediction of ~ strands is described in Fig. 3 legend. Bolded, underlined letters represent ICAM-1 residues substituted for 
homologous VCAM-1 residues in each mutant,  mAbs:/5% =  EH8, lg =  1(311, 14 =  1.4C3, Bb =  BBA-6, 4b =  4B9, 6d =  6D9, le = 
1ES. "Block" indicates whether each mAb is able (+) or unable (-) to block binding of VLA-4-bearing cells to VCAM-1 domain 1. "Domain" 
indicates to which domain each mAb maps (see text for further details). Expression of each construct was quantified by binding to raAb 
EHS, and binding to other mAbs and to Ramos ceils is expressed as a percentage of VCAM-6D wild-type binding, after correction  for 
expression (see Materials and Methods).  +  =  50-300%,  +  =  10-50%,  -  =  0-10%  wild-type binding. 
determined by assaying adhesion to the transformed B leuke- 
rnia line Ramos. Results are presented in Table I and Fig. 4. 
In Fig. 5, constructs displaying staining or binding at a level 
>50% of the wild-type level are indicated as +,  10-50% as 
+/-,  and 0-10%  as  -. 
Sensitive and Insensitive Epitopes of 
VCAM-1 Domains 1 and 2 
It is important to distinguish mutants that have lost VLA-4 
binding activity due to large scale perturbations in structure 
from those that show effects limited to contact residues. To 
identify  mutants  exhibiting  improper  folding  of domains 
1 and 2,  we stained with a  panel of mAbs representative 
of every known epitope of VCAM-1  within these domains. 
mAbs that map to domain 1 include blocking (i.e., able to 
block binding of VCAM-1  to VLA-4) mAbs 4]39 (Carlos et 
al.,  1990) and 1E5 and non-blocking mAb 6D9.  Domain 2 
mAbs include blocking mAbs BBA-6 and  1Gll,  and non- 
blocking mAb 1.4C3. All of these mAbs bind to different epi- 
topes, distinguished by cross-blocking in competitive bind- 
ing  assays  or  by  functional  ability  to  block  binding  of 
VCAM-1  to VLA-4. Analysis of mutants allows us to divide 
these mAbs into two classes: those whose epitopes are per- 
turbed by several mutations, to linearly distant areas of do- 
main 1 (designated "sensitive" epitopes), and those that are 
usually or always unaffected by such mutations ("insensitive" 
epitopes). Most but not all mutants that have lost more than 
one sensitive epitope (those recognized by domain I mAbs 
4B9, 6D9, 1E5 and domain 2 mAb BBA-6) have also lost the 
ability to bind to Ramos cells,  probably due to improper 
folding. The exceptions, Mll and 12, retain partial binding 
to cells. Of mutants that retain sensitive epitopes, most bind 
well to VLA-4, indicating that the substituted ICAM-1 amino 
acid residues  can support both proper folding and ligand 
binding. 
Mutations That Conserve Sensitive Epitopes but 
Diminish Binding to VLA-4 
The most informative mutants are those that retain sensitive 
epitopes,  but  show  diminished  binding  to  VLA-4:  M23, 
M25,  and M15.  These constructs implicate two regions of 
domain  1 in binding VLA-4: aspartic acid 40 (D40),  and 
The Journal of Cell Biology, Volume 124,  1994  606 G64NEH. Residue D40 of VCAM-1 is analogous to E34 of 
ICAM-1,  which  was  shown  by  Staunton  and  coworkers 
(Staunton et ell., 1990) to be required for binding of ICAM-1 
to its integrin counter-receptor LFA-1. Both E34 of ICAM-1 
and D40 of VCAM-1  are located in the predicted loop be- 
tween fl strands c and d  ("c-d loop"). When VCAM-1  D40 
is replaced by alanine (M25), binding to VLA-4 is abolished. 
Interestingly, our original mutant in this area, which sub- 
stituted  the  ICAM-1  sequence G32IET for the analogous 
VCAM-1 Q38IDS (M9), resulted in complete retention of all 
epitopes, and of binding to VLA-4 that was specifically in- 
hibited by anti-o~4 mAb HP1/2. This ability of ICAM-1  se- 
quence to functionally substitute for VCAM-1  residues in 
binding to VLA-4 indicates that these residues do not deter- 
mine specificity for a particular integrin ligand, but are prob- 
ably part of a general integrin binding structure that may in- 
clude important contact residues, yet requires other contacts 
for its  specificity. Comparison  of the predicted c-d loop 
among other sequences known to bind human VLA-4, LFA-1, 
or Mac-1  (Fig.  2) reveal in each case a  sequence with the 
common feature "ap-L," where a  is an acidic residue (D or 
E), p  is a polar residue (usually a hydroxyl derivative S or 
T, but an amino derivative Q in the Mac-1 binding site), and 
L is a leucyl residue. This small region has been shown ex- 
perimentally to be an important component of the integrin 
binding site in ICAM-1  domains  1 and 3, human VCAM-1 
domains 1 and 4, murine VCAM-1 domain 1 and rat VCAM-1 
domain 1 (Staunton et al., 1990; Diamond et al., 1991; Moy 
et al.,  1993; this work; Osborn, L., and B. Browning, un- 
published data). 
The other VCAM domain 1 sequence implicated in bind- 
ing is located in the putative e-f loop. When the sequence 
G64NEH is changed to VQED (M15), all epitopes are main- 
tained except for partial loss of mAb 6D9 binding, but bind- 
ing to Ramos cells is greatly reduced. Attempts to define a 
specific amino acid residue responsible for loss of binding 
have met with only partial success. The mutation N65 to A 
(M29) results in a profile of epitopes similar to M15, but loss 
of Ramos binding is less severe than that of M15. H67 to A 
(M30) results in fuU maintenance of epitopes and cell bind- 
ing, while G64 to A (M28) causes loss of sensitive epitopes 
and cell binding activity, indicating deleterious effects on pro- 
tein folding (mutants M28-30, Fig. 5). Studies currently in 
progress may resolve this issue. In ICAM-1,  the analogous 
region of domain 1 (putative e-f loop) was not found to be 
involved in binding to LFA-1. However, a mutation in this re- 
gion of ICAM-1 did affect binding to both human rhinovirus 
(HRV) and to anti-ICAM-1 mAb RR1/1, which blocks bind- 
ing to both LFA-1 and to HRV (Staunton et al., 1990). Bind- 
ing of Mac-1 to ICAM-1  via domain 3 was reduced 70% by 
mutagenesis of the predicted e-f loop (ICAM E254DE to 
KEK, where ICAM E254 corresponds to VCAM E66) (Dia- 
mond et al.,  1991). Thus there is considerable functional as 
well  as  structural  homolog  among  the  various  integrin- 
binding Ig-like domains. 
Several lines of evidence suggest that domain 2 is impor- 
tant both for maintaining proper folding of domain 1, and 
perhaps for providing contact residues that form part of the 
binding pocket for VLA-4. As shown in Fig. 6, the c-d and 
e-f  loops axe expected to be close to each other in the classi- 
cally folded Ig-like domain. Both predicted loops are at the 
surface of domain 1 that is expected to be closest to domain 
Figure 6. Hypothetical model of  VCAM-1 D1 and D2 tertiary struc- 
ture. Predicted/3 strands and turns or loops are modeled on the ba- 
sic tertiary structure of an Ig domain (Barclay, 1992). Residues im- 
plicated in binding VLA-4 are indicated as white ovals with black 
letters. Disulfide bonds are indicated by bars. Note that the rela- 
tively long NH2-terminal sequence before predicted 13 strand "a" 
has effects  on folding when mutated (Fig. 5, mutant M1), and might 
therefore form a more integral part of the structure than is indi- 
cated. Some residues conserved in domain 2 of murine, rat, and 
human VCAM-1 are indicated. 
2. It has been shown that a fragment consisting of VCAM-1 
domains 1 and 2 can support binding of VLA-4-bearing cells 
(Pepinsky  et  al.,  1992),  while  generation  of  fragments 
representing  either  domain  1  or  2  alone  has  not  been 
achieved, presumably because they are unstable. A construct 
in which domain 2 of VCAM-1 has been replaced by domain 
2 of ICAM-1  retains the sensitive epitopes in domain 1 rec- 
ognized by mAb 4B9 and 1ES, but shows greatly diminished 
binding to VLA-4, suggesting that mere stabilization of do- 
main 1 may be insufficient to allow full adhesion (Osborn et 
al., 1992). Both ICAM-1  and VCAM-1 give rise to blocking 
mAbs that map within domain 2,  and several residues in 
ICAM-1 domain 2 were found to affect LFA-1 adhesion mod- 
estly,  though none had as  dramatic effect as those in do- 
main 1, described above (Staunton et al., 1990). The current 
evidence is fully consistent with a model in which domain 
2 of VCAM-1 provides necessary contact residues, which de- 
pend upon domain 1 for both completion of the VLA-4 bind- 
ing "pocket," and for conformational stabilization. 
The marked functional and structural similarity of  VCAM-1 
domains 1 and 4 suggest that the mechanism of VLA-4 bind- 
ing to domains 1 +  2 unit will also account for binding to 
Osborn et al. Shape and Functional Amino Acids of VCAM-1  607 the domain 4  +  5 unit. In recombinant constructs domain 
4 can fully substitute  for domain  1 in cell binding activity, 
whether in conjunction with domain 2  or with its  natural 
partner domain 5  (Osborn et al.,  1992).  Reciprocally, do- 
main 1 can substitute  for domain 4 (Pepinsky et al.,  1992). 
The high sequence similarity of domain 1 and 4, in human 
and in other species, has made it difficult to choose probable 
binding sites by distinguishing  conserved from divergent resi- 
dues. Domains 2 and 5 are not as similar,  evincing patches 
of homology which are good targets  for mutagenesis  (Fig. 
6,  indicated residues in Domain 2).  Intriguingly,  there are 
conserved sequences in domains 2 and 5 that bear better ho- 
mology to the VLA-4 binding site in fibronectin (LDV) (Ko- 
moriya et al.,  1991;  Wayner and Kovach,  1992)  than does 
any sequence in domain 1 and 4. Mutational  analysis of do- 
main  2,  currently  underway,  may  provide  answers to  the 
questions we have raised here. 
In conclusion, we believe that by comparing members of 
the  integrin-binding  Ig  sub-family  composed  thus  far  of 
ICAM-1,  -2, -3, VCAM-1,  and MAdCAM-1,  we may derive 
generally applicable structure/function information leading 
to development  of novel therapeutic  molecules that affect 
these  adhesion  pathways.  We have  demonstrated  that  the 
bivalent,  seven-domain  form of VCAM-1  assumes  an  ex- 
tended conformation, usually with one or two slight bends. 
Mutational  analysis of domain  1 identifies two regions in- 
volved in binding to VLA-4,  both of which have structural 
and  functional homologs  in active domains  of the related 
molecule ICAM-1. Sensitive, functional epitopes mapping to 
domains 1 and 2 are often lost concurrently,  providing addi- 
tional evidence that in VCAM-1,  domains  1 and 2 (or their 
homologues 4 and 5) are both required for full VLA-4 bind- 
ing activity. 
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